Children with cancer tumors lacking DNA repair may benefit from olaparib combined with ceralasertib.

Published Date: 19 Apr 2023

Pediatric patients with solid tumors exhibiting DNA replication stress and/or DNA repair responded favorably to a combination of the investigational ATR inhibitor ceralasertib and the PARP inhibitor olaparib (Lynparza).

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

An ancient signaling pathway and 20 years of research offer hope for rare cancer

2.

Off-the-Shelf Drug Matches CAR-T Effects in Refractory Lupus

3.

Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study

4.

I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.

5.

Prostate cancer detection with PET CT and PET MRI is comparable.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot